NZ270980A - Medicament comprising caffeine, potassium iodide and ammonium chloride - Google Patents

Description

New Zealand Paient Spedficaiion for Paient Number £70980 27 0 9 8 Priority Dato(s): Compie',5 Specification Fiiid: Class: ( Fjblication Date:....?..!!...4y.L..!??7 P.O. Journal Nio: NEW ZEALAND PATENTS ACT, 1953 COMPLETE STECIF1CATJON Patent of Addition No.: 231322/233973 Date: 08 November 1990 "Medicament and Use Thereof' I, OSWALD EDMONDS HOOPER, a Few Zealand citizen of 7/460 Remuera Road, Remuera, Auckland, New Zealand do hereby declare this invention to be described in the following statement:- !.. omce The present invention relates to a medicament for treating humans for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated.

In my New Zealand Patent Application No. 231322/233973, the full contents of which are hereby here included by way of reference, there is disclosed and claimed a medicament comprising an effective amount of a mixture of potassium iodide, ammonium chloride and caffeine for treating viral infections and bacterial infections commonly associated therewith. In particular there is disclosure of the use of such a composition for treating equine viral infections and bacterial infections commonly associated therewith.

A preferred medicament disclosed and claimed in the aforementioned specification comprised potassium iodide 200 mg/1 to 800 mg/1 ammonium chloride 200 mg/1 to about 800 mg/i, and caffeine 200 mg/1 to about 800 mg/1.

A particularly preferred medicament of the aforementioned New Zealand Patent Application No. 231322/233973 additionally included aqueous chloroform 10 ml/1 to about 40 ml/1.

There is also disclosure of administration of such a composition in an amount between about 30 ml and 120 ml on a daily basis.

The medicament of my NZ Patent Specification 231322/233973 was applied both to unhealthy and well as healthy horses.

Encouraged by the success of a medicament as disclosed in New Zealand Patent Application No. 231322/233973 in respect of the treatment of horses as well as other anirmls such as cats, dogs, calves and humans, I have now turned to formulating a form of the medicament suitable for use with humans.

Accordingly in a first aspect die present invention may broadly be said to consist in a medicament comprising or including Caffeine (Anhydrous) 2.0g/ 100ml Potassium Iodide 2.0g/100ml and Ammonium Chloride 2.0g/100ml.

N.Z PATFf'T OFFICE M JUN 1997 . RECEIVED 27 0 9 Caffeine (Anhydrous) Potassium Iodide Ammonium Chloride Methyl Paraben Isopropyl Paraben ' • tf- In a preferred form of the present invention the medicament comprises or includes 2.0g/100ml 2.0g/100ml 2.0g/100ml lOOmg/ 100ml and 50mg/100ml.

In a preferred form of the present invention the medicament comprises -Caffeine (Anhydrous) 2.0g/100ml 2.0g/100ml 2.0g/100ml lOOmg/lOOml 50mg/100ml 12.5g/100ml 40g/100ml 5.7g/100ml 0.5g/100ml In a further aspect the present invention consists in a medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament comprising or including Caffeine (anhydrous) 20g/l Potassium Iodide 20g/l, and Ammonium chloride 20g/l.

Preferably said medicament also includes: Methyl paraben and isopropyl paraben together with compatible carriers and orally acceptable inclusions.

In yet a further aspect the present invention consists in the use of caffeine, potassium iodide and ammonium chloride in the preparation of a medicament comprising Caffeine (anhydrous) 20g/l Potassium Iodide Ammonium Chloride Methyl Paraben Isopropyl Paraben Glycuol BP Syrupus BP Alcohol WS 95 Green No.5 1% soln N 7 ' V; ofrce ^ 2 3 MAY £37 ! • 1 27 0 98 Potassium iodide 20g/l, and Ammonium chloride 20g/l, for treating a human or mammal for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/orfor detoxifying such a mammal, by periodically administering or having administered to such a mammalian patient an effective amount of a medicament comprising caffeine (anhydrous) 20g/l, potassium iodide 20g/l and ammonium chloride 20g/l.

Preferably said medicament also includes methyl paraben and isopropyl paraben together with optionally compatible carriers and orally acceptable inclusions.

Preferably in the case of a human, a daily optimum dosage of about lml/6kg of body weight is administered daily after a lead up period of lower dosing.

Table 1 HUMAN PROBLEM DOSE / DAY RESULT SIDE EFFECTS DURING TREATMENT APPROXIMATE DURATION OF TREATMENT (MONTHS) PATIENT AGE (YEARS) SEX Bronchitis lOmls -15mls No Bronchitis No Chest Pain Runny Nose, Phlegtr1, Weight Increase 3 Months 52 F Blood Pressure Headaches lOmls No Headaches Decreased Blood Pressure to Normal ] Month 47 M Nausea, Headaches, Cough Lethargy lOmls Lost all of Problems 1 Month 40 M Bad Hearing Glue Ear 2mls Normal Hearing Mucus Cleared Runny Nose, Mucus 1 Vt Months 4'/i M N.7. PAT1":;--7 orc-'irr ^7 0 9 S o • Wheezing, Bad at Breathing, Asthma 3 mis Easy Breathing 1 Month 7 M Emphysema (lungs) lOmls Much Improved Breathing, Side Effects Cleared Pimples on Head and Back 1 Month 63 M • Short of Breath, Emphysema, Psoriasis lOmls Clear lungs & Sores 3 Months 49 M Asthma Using Inhailer 15mls Good Breathing No need for inhaler Mucus, Nasal Discharge 4'/z Months 47 M Tiredness, Asthma variable All Problems Gone Nasal Discharge, Pimples 2 Months 7 F Asthma lOmls Improved Weight Loss 2 Months 44 F Bronchial Asthma lOmls Improved Does Not Use Inhaler Anymore Nasal Discharge 4 Months 77 F • Herpes on Lips, Flu, Headaches lOmls No Herpes nor Brucellosis Nasal Discharge, Pimples on Back, Muscle Weakness 1 Vi Months. Still healthy after 3 years from time of treatment 52 M • Flu, Headaches 30mls Sleep Better, No Problems, Quick Recovery from Flu Runny Nose 2 Months 36 F i i 30mls Feel Better Constipated 1 Month 58 F r^.

C"~ c%> >- *■ Z m? Flu , lOmls Quick Recovery Runny Nose 2 Months 42 M Runny Nose/Cough 5mls All Problems Gone 1 Month 8 M CO tv Runny Nose/Cough mis All Problems Gone 1 Month M Flu lOmls All Problems Gone 1 Month 17 F Cold Sores lOmls Less Tired, More Energy Rash on Back 2 Months 27 F 270980 '• -6- Shingles - lOmls Problem Gone Months 66 M Shingles, lOmls More Energy, Rashes Gone 3 Months 65 M Tiredness, Psoriases, Headaches lOmls Rashes Gone, No Coldsores or Headaches Pimple Outbreak 3 Months 36 F SLE 15mls Energy Increase and felt better This is a medical riddle. Nov/ healthy. 12 Months 38 M MECFS PUS - 15mls Energy Increase, Much Improved Discharge from Nose Continuing. Now 98% cured on golf course 5 days a week. 28 M Jaundice, Sore Joints, Tiredness 15mls Impotence Cured, No Pain, Energy Increase Nasal Discharge 2 Months 56 M Bronchitis - 12mls Much Improved Continuing 59 F Lead Poisoning/ Menopause lOmls Feeling Better Fibroid gone Aching Stomach Muscles 3 Months 39 F Prostate Gland Malfunction lOmls Normal Urination, Energy Increase 11 Months 78 M Chronic Sinus Problem for Years mis Sinus Cleared, Sleeping Better 2 Months 52 F Hepatitis C 15mls Help Nausea, Sweats 2 Months 39 M Eczema about Mouth, Chest and Back mis All Areas Almost Cleared 2 Months 9 F 270 98 0 Lymphatic Cancer lOmls Haemoglobin rose from 12.4 to 15.9 [normal is 12 to 18] and white cells dropped from 9.7 to 5.6 [normal is 4 to 11] Had had maximum chemotherapy. 3 years since treatment - feels 100% 3 Months 60 M Prostate Cancer lOmls Prostate specific antigen lowered from 37.6 to 0.9 [normal is 0 to 4] Feels better. 2xh Months 74 M Diabetes lOmls Sugar level dropped from 13.1 to 9.0 [normal is 5 to 8] Feels better and more energetic.

Months 74 M The composition of the present invention was taken by human subjects on a daily basis. Each subject administered or was administered a prescribed daily dose over various periods, for the treatment of their infection. Subjects were requested to provide their background information and keep a record of the results of treatment.

Various symptoms of viral diseases were displayed by the subjects prior to treatment and included various skin disorders, Asthma, Bronchitis, Flu & Colds including general tiredness and other flu symptoms, and emphysema to name a few. Although subjects were subjected to differing doses and differing durations of treatment most subjects showed a marked improvement by a diminishing if no complete clearing of symptoms.

Several subjects had previously been treated with other types of medication or methods of treatment without much success. Treatment with the composition of the instant invention rapidly obviated symptoms displayed by most subjects, and most subjects no longer needed to rely on previous medication. As an example one subject suffering from Asthma stated that he no longer used his inhaler.

N.Z. PATENT OFFICE 2 3 MAY 1997 ffSECSV'ED

Claims (9)

27 0 9 g o ' ' ' ig- During the initial stages of treatment, several subjects had at least one side effect. The most common side effect displayed by subjects was a nasal discharge. Other side effects include acne out breaks on the back and on the head or phlegm and mucus discharges. In most circumstances such side effects lasted a chort period after which both the symptoms of the side effect and the original symptoms disappeared. The dosage administered to subjects varied depending on symptoms and subject age. The age of the jjroup of subjects varied from 4 lA years to 78 years. Several of the records provided from subjects were completed by medical doctors, which provided a more expert opinion on the symptoms, side effects and results. The most preferred form of the present invention for human usage is a composition as follows: Caffeine (Anhydrous) 2.0g/100ml Potassium Iodide 2.0g/100ml Ammonium Chloride 2.0g/100ml Methyl Paraben lOOmg/ 100ml Isopropyl Paraben 50mg/100ml Glycuol BP 12.5g/100ml Syrupus BP 40g/ 100ml Alcohol WS 95 5.7g/100ml, and Green No.5 1% soln 0.5g/100ml. The composition has the following physical characteristic green solution with viscosity slightly greater than water. Recommended optimum daily dosage is lml/6kg body weight per kg of patient. Initial dosages are to extent tolerated by patient with gradual (preferably weekly) increase to the optimum level. A suggested start may be as low as 2mls per patient. N.Z PATENT OFFICE 2 3 HAY 1997 27 0 980 2.0g/100ml 2.0g/100ml and 2.0g/100ml. ' • •119- WHAT I CLAIMS IS:

1. A medicament including Caffeine (Anhydrous) Potassium Iodide Ammonium Cliloride

2. A medicament of claim 1 which includes Caffeine (Anhydrous) 2.0g/100ml Potassium Iodide Ammonium Chloride Methyl Paraben Isopropyl Paraben

3. A medicament of claim 1 which includes Caffeine (Anhydrous) 2.0g/100ml Potassium Iodide Ammonium Chloride Methyl Paraben Isopropyl Paraben Glycuol BP Syrupus BP Alcohol WS 95 Green No.5 1% soln 2.0g/100ml 2.0g/100ml lOOmg/lOOml and 50mg/100ml. 2.0g/100ml 2.0g/100ml lOOmg/lOOml 50mg/100ml 12.5g/100ml 40g/100ml 5.7g/100ml and 0.5g/100ml

4. A medicament suitable for the treatment of mammals for viral infections and/or bacterial infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for the use as a detoxicant mixture with any such mammal, said medicament including Caffeine (Anhydrous) 20g/l Potassium Iodide 20g/l and Ammonium Chloride 20g/l.

5. A medicament of claim 4 which also includes: methyl paraben and isopropyl paraben together with compatible carrier or carriers and orally acceptable inclusion or inclusions. N.Z. PATENT Or 23 MAY897 ( ■ — ^ 0 9 q

6. A use of caffeine, potassium iodide, and ammonium chloride, in the preparation of a medicament comprising said caffeine (anhydrous) 20g/l, potassium iodide 20g/l, and ammonium chloride 20g/l for treating a human or mammal for viral infections and/or bacteriel infections commonly associated therewith and/or for ailments where detoxification might be indicated and/or for detoxifying such a mammal.

7. The use according to claim 6 wherein said medicament also includes methyl paraben and isopropyl paraben together with optionally compatible carrier or carriers and orally acceptable inclusion or inclusions.

8. The use according to claims 6 or 7 wherein the amount or amounts of the medicament is administered only after a lead up period of a lower dosing. -

9. The use according to claims 6, 7 or 8 wherein for a human patient an optimum dosage of about lml/6kg of body weight is administered daily after a lead up period of lower dosing. END OF CLAIMS N.Z. PATENT OFFICc